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BACKGROUND  
We undertook this study to evaluate the significance of the C-reactive protein level 
(CRP) as a prognostic factor in oncology patients with acute renal failure (ARF) during 
nephrology consultation. 
 
METHODS  
The study was comprised of a cohort of 375 consecutive oncology patients who had 
been admitted to a university-affiliated hospital between March 1998 and April 2006 
and had been diagnosed with ARF. One hundred and fifty nine patients with ARF who 
matched at least one of the RIFLE criteria on increased serum creatinine were included 
for subsequent analysis. We used a Cox proportional hazard model. 
 
RESULTS  
Clinical pathological variables were compared among patients with serum CRP levels 
≥8 mg/dL (exposed group; cut-off point: median) and patients with serum CRP level <8 
mg/dL (control group). In-hospital mortality rates associated with CRP levels were 
53.8% for ≥8 mg/dL and 21.5% for <8 mg/dL (p <0.001). After adjusted analysis, the 
presence of a CRP level ≥8 mg/dL was significantly associated with an increased in-
hospital mortality (HR 2.10; 95% CI: 1.17-3.78) than in those patients with similar 
Liano scoring, the same RIFLE classes, and the same treatment for ARF. In addition, 
each increment of 1 mg/dL of serum CRP was associated with an adjusted 4% 
increment of in-hospital mortality (HR 1.04, 95% CI: 1.01-1.06). 
 
CONCLUSIONS  
CRP levels at nephrology consultation were an independent predictor of death in this 
cohort of oncology patients with ARF. Patients with levels ≥8 mg/dL may be considered 
at higher risk of death.  
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INTRODUCTION 
 
Important advances in the diagnosis and treatment of acute renal failure (ARF) have 
been made. However, in-hospital mortality rate remains high (1-6). Because of the 
absence of a consensus definition of ARF, research has been made difficult (7,8). 
Recently, the Acute Dialysis Quality Initiative (ADQI) published a uniform definition 
called the RIFLE criteria (Risk, Injury, Failure, Loss, and End-stage) (9), and it has 
been adopted by the Acute Kidney Injury Network (AKIN) (10). 
Severe illness of almost any etiology is accompanied by a generalized host 
inflammatory response. The single most used and well-studied inflammatory marker is 
C-reactive protein (CRP) (11-13). It has been well recognized as a prognostic indicator 
in oncology (14-17), cardiovascular disease (11,13,18), and chronic renal failure (9-23). 
Nevertheless, information about the risk profile for CRP in ARF is scarce. 
Therefore, the objective of this study is to evaluate the impact of serum CRP level at the 
nephrology consultation on prognosis in oncology patients with ARF. 
  
 
MATERIALS AND METHODS 
 
Study Population 
The University Hospital of Navarra is a tertiary care academic teaching medical center 
with 400 beds in the city of Pamplona, Spain. The hospital ethics committee approved 
the research project. From March 1998 to April 2006, a cohort of 375 consecutive 
oncology patients with ARF was prospectively entered into a computerized data-base. 
We restricted our analysis to patients with adequate increment of creatinine to qualify 
for the RIFLE criteria for ARF (9) and who were older than 16 years. One hundred and 
nineteen patients did not fulfill the RIFLE serum creatinine criteria and were not 
oliguric. Thirteen patients presented oliguria (although it could not be measured on a 6-
h basis), but did not fulfill the creatinine criteria. Sixty nine patients had no CRP 
measured at the time of nephrology consultation. One patient was <16 years of age. 
Fourteen patients did not have complete data recorded. After exclusion, 159 patients 
remained for subsequent analysis. 
 
Clinical and Laboratory Data 
In this study, ARF was defined as an increase in serum creatinine level sufficient to 
qualify for the RIFLE criteria. 
Serum levels of CRP were measured at the time of nephrology consultation, as part of 
the routine laboratory samples, by latex photometric immunoassay. 
Functional status prior to admission was measured using the Karnofsky Performance 
Score (24). Patients were classified into the maximum RIFLE class (R, I, or F) 
according to only their creatinine levels. We were unable to collect full information on 
urinary output (9). Peak creatinine was defined as the highest creatinine level reached 
during their admission, using the kinetic Jaffe assay. For patients with no previous 
history of chronic renal failure, the baseline creatinine was calculated using the 
Modification of Diet in Renal Disease (MDRD) equation (25), as recommended by the 
ADQI workgroup (9), assuming a glomerular filtration rate of 75 mL/min/1.73 m2 (5). 
For patients with a history of renal failure, baseline creatinine was defined as the one 
measured at hospital admission (26). Demographic data, etiology of ARF, comorbid 
conditions, and laboratory data were all prospectively collected. Severity of illness was 
measured through Liano score (0.032*age in decades — 0.086*male gender — 
0.109*nephrotoxic + 0.109*oliguria + 0.116*hypotension + 0.122*jaundice + 
0.150*coma — 0.154*consciousness + 0.182*assisted respiration + 0.210) (27). The 
difference between serum creatinine value at the time of initial nephrology consultation 
and baseline value was calculated and expressed in percentage (%): creatinine change 
(%) = [(creatinine when nephrologist saw the case — basal creatinine)/basal creatinine] 
* 100. We chose to calculate the percentage of the change of creatinine with respect to 
its baseline because it is modulated by muscle bulk, so even changes as low as 0.3 or 
0.5 mg/dL have distinct significance for patients with different genders and/or ages and 
whose normal baseline levels are different (7). Food intake was defined as the caloric 
ingestion during the previous days, and this was classified as appropriate when it was 
optimal, mild malnutrition when it was inappropriate for <3 days, moderate malnutrition 
when it was inappropriate between 3 and 7 days, and severe malnutrition when it was 
inappropriate for >7 days. The patients’ clinical status and treatment for ARF were 
recorded daily. All cases were treated during admission at our hospital by the same 
nephrologist, and all data were gathered by the same observer. In our institution, the 
nephrologist is the only physician who can administer renal replacement therapy 
according to a strict protocol, so any possible renal replacement therapy had not been 
started before nephrology consultation. 
 
Analysis 
We focused on relation of CRP and in-hospital mortality. We considered the serum 
CRP level at the time of nephrology consultation as the exposure variable. Patients were 
classified into two groups according to their CRP level using the median as cut-off 
point. 
Continuous variables were expressed as medians (and interquartile ranges) and 
compared using Student’s t-test when the variable fitted a normal distribution (evaluated 
through Kolmogorov-Smirnoff test) or Mann-Whitney U test when it did not. 
Categorical variables were expressed as proportions and compared with the chi-square 
test. 
Survival time in relation to baseline CRP levels was performed graphically using the 
Kaplan-Meier survival curve and assessed with the log-rank test. 
Cox proportional hazards models were used to determine the independent effect of 
baseline CRP levels on inhospital mortality. Hazard ratios (HR) and their 95% 
confidence intervals (CI) were calculated considering the group of CRP level <8 mg/dL 
as the reference category. Additionally, we considered baseline CRP levels as a 
continuous variable, calculating the HR associated with 1 mg/dl CRP increment. We 
fitted a crude model (univariate, i.e., without any adjustment) and a multivariate-
adjusted model including all those variables found statistically significant in the 
descriptive analysis plus age and sex. Furthermore, we present a table including the 
crude and adjusted associations of those variables that remained significant in the 
multivariate model: CRP levels, Liano scoring, and Karnofsky scoring, plus age and 
sex. Liano scoring includes in its equation the variables for nephrotoxicity, oliguria, 
hypotension, jaundice, mental status, and assisted respiration. 
Examination of proportionality assumptions in the Cox model indicated no significant 
time x risk factor interactions for any variable in the model. 
We analyzed overall survival at 60 days across groups using the Kaplan-Meier methods 
and tested differences between groups using the log-rank test. The time of origin was 
the day when the nephrology consultation began. The event defined was death, whereas 
those cases alive at the end of follow-up and those lost to follow-up were censored at 
their last observation. 
All p values presented are two tailed; p <0.05 was considered statistically significant. 
Statistical analyses were conducted using SPSS v.10.0.7 (SPSS Inc., Chicago, IL). 
 
 
RESULTS 
 
More than one third of the patients with CRP levels <8 mg/dL had kidney cancer, 
whereas patients in the ≥8 mg/dL group presented no predominant type of malignancy 
(Table 1). Demographic and clinical characteristics for the 159 patients are shown in 
Table 2. Overall mean level of CRP was 11.56 mg/dL (SD 11.59). The mortality rate 
was significantly higher in the group with ≥8 mg/dL (median as a cut-off). Among the 
patients with ≥8 mg/dL, 43 died (53.8%) compared to 17 (21.5%) in the <8 mg/dL 
group (p <0.001). There were important baseline differences between both groups that 
may be associated with survival. Serum levels of CPR ≥8 mg/dL were associated with 
higher increments of serum creatinine level with respect to baseline and lower levels of 
serum albumin. Serum levels of ≥8 mg/dL were also associated with poorer Liano and 
Karnofsky scorings and more severe RIFLE categories. Prior nutrition intake was 
impaired in patients with CRP levels ≥8 mg/dL, and they needed dialysis treatments 
more often. There were no differences in terms of mortality in connection with 
outpatient ARF or hemoglobin levels. Mean hemoglobin level for survivors was 11.17 
mg/dL (95% CI: 10.73-11.61) and was 10.64 mg/dL (95% CI: 10.14-11.14) for non-
survivors. After adjusting for age, sex, Liano scoring, Karnofsky score, nutrition intake, 
RIFLE classes, treatment of ARF, relative increment of serum creatinine, and serum 
albumin with multivariate Cox proportional hazard model, a serum CRP level ≥8 mg/dL  
was an independent and significant in-hospital mortality predictor [hazard ratio (HR) 
2.10, 95% CI: 1.10-4.01], p = 0.025. For each 1 mg/dL increase, the risk ratio of 
mortality was 4% higher (HR 1.04, 95% CI: 1.01-1.06), p = 0.014. 
When we adjusted only for age, sex, Liano and Karnofsky scorings, HR was similar 
(Table 3). Furthermore, the association between mortality and higher Liano scorings 
and lower Karnofsky scores was clear, as shown in the related HRs. However, neither 
age nor sex seemed to have influence on the HR for in-hospital mortality. 
We analyzed short-term survival. According to the Kaplan-Meier plot, CRP levels ≥8 
mg/dL also presented a statistically significant higher mortality rate in the period 
between the nephrology consultation and 60 days (Figure 1) compared to CRP levels <8 
mg/dL (log rank test = 18.05; p <0.001). Most of the deaths (39 and 17 deaths for CRP 
levels ≥8 mg/dL and <8 mg/dL, respectively) occurred during the first 60 days of 
follow-up. 
 
 
DISCUSSION 
 
This study involved oncology patients with ARF and sought to identify if CRP levels 
were a predictor of mortality. Our results are consistent with several established studies 
(12-23,28,29) but never previously among oncology patients with ARF. CRP was 
associated with higher mortality after adjusting for possible confounders. Patients with 
the same Liano scoring and RIFLE classes and who received the same treatment for 
ARF had different mortality rates according to the CRP level at the time of nephrology 
consultation. This may suggest that inflammation plays a role in the outcome of 
oncology patients with ARF. On the other hand, serum CRP level was correlated with 
poor prognosis in oncology patients per se in other studies (12,14,16,17,28,29), 
although its mechanism is not well understood yet. In addition, CRP is known to 
increase with declining kidney function (19,30-32). A high value (≥8 mg/dL) might 
indicate an unfavorable health condition. Measuring serum CRP at the beginning of 
nephrology consultation may help in selecting patients who would benefit or not from 
intensive therapy. The hazard ratio for mortality of 2.10 in patients with CRP ≥8 mg/dL 
may show the importance of inflammation on outcome. It may be another use for a 
widely available, standardized, reliable and relatively inexpensive inflammation marker 
(13). 
It was important to adjust for the severity of illness due to the heterogeneous nature of 
ARF (3). The Liano score was chosen because of its ability to delineate mortality from 
survival and also for its ability to calibrate the observed mortality rate with the expected 
mortality in ARF (3,6,33). It was also important to adjust for the severity of the ARF. 
The RIFLE consensus criteria gives a standard definition and a level of classification of 
severity in ARF (9), a request often made by the experts (7,8). Adjusting for the severity 
of comorbid illnesses and using the RIFLE criteria may allow compare further 
investigation in ARF. 
Chronic renal failure was included in this study to represent the common clinical 
practice. The proportion of patients was similar between groups. 
It is also interesting to determine the risk of death per each 1 mg/dL of serum CRP 
because this kind of measurement may be useful to improve the knowledge of the risk 
profile of every patient. Due to the observational nature of the present study, no 
conclusions can be made with confidence, but it should encourage future research on 
understanding the influence of CRP levels on mortality in ARF and/or oncology 
patients. 
There are several limitations to this study. The sample size was small and may limit the 
analysis. Therefore, large confidence intervals were found. It could be argued that the 
study took place in a single hospital with its limits to apply to other centers. Urine 
output data were not available; therefore, it was not possible to estimate the RIFLE 
criteria according to this value. We began to collect data before the RIFLE criteria were 
formulated, and most of the ward patients had no urinary output measured on a 6-h 
basis. We assume that we might underestimate some cases according to the RIFLE 
criteria and exclude others (although only 13 patients were excluded). At the same time, 
serum baseline creatinine values were calculated by the MDRD equation, on an 
assumed glomerular filtration rate (GFR) of 75 mL/min/1.73 m2 (5). This formula has 
been shown to underestimate the GFR in healthy subjects and even more in ill patients 
(34) because it was derived from patients with chronic renal failure (35,36), and it may 
therefore underestimate the severity of ARF when using the RIFLE criteria (37). This 
lack of reliability remains one of the controversial issues regarding the RIFLE criteria 
and needs further clarification (38). 
The possibility of residual confounding cannot be ruled out, but it is unlikely that it can 
fully explain the observed strong associations. We cannot precisely establish serum 
CRP level that may be clinically relevant because the decision to take the cut-off point 
of 8 mg/dL was done mathematically. 
In conclusion, CRP level at the time of nephrology consultation was associated with a 
significant increase in the risk of death in this cohort of oncology patients with ARF. 
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Table 1. Percentages (%) of types of malignancy in 159 patients 
Malignancy CRP <8 mg/dL CRP ≥8 mg/dL 
Kidney cancer 38.0 10.0 
Breast cancer 12.7 8.8 
Colorectal cancer 11.4 13.8 
Endometrial cancer 6.3 10.0 
Skin cancer 5.1 6.3 
Lung cancer 3.8 10.0 
Hepatocellular cancer 3.8 1.3 
Pancreatic cancer 3.8 6.3 
Hematological 2.5 3.8 
Bladder cancer 1.3 5.0 
Stomach cancer 1.3 6.3 
Prostate cancer 1.3 2.7 
Undetermined 2.5 1.3 
Miscellaneous 6.2 14.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Characteristics of patients according to C-reactive protein (CRP) level 
Variables* CRP <8 mg/dLn = 79 
 CRP ≥8 mg/dL 
n = 80 
PP~ 
value
Increase of creatinine#: median % (IQR) 62.74 (147.66) 118.00 (235.11) 0.013
Age: median years (IQR) 56.10 (11.95) 56.16 (11.83) 0.97
Sex: male (%) 58.2 62.5 0.63
Patients with no previous history of chronic renal 
failure (%) 79.7 82.5 0.69 
Basal serum creatinine (mg/dL) according to the 
MDRD equation: median (IQR) 1.03 (0.22) 1.04 (0.23) 0.63 
Patients with history of chronic renal failure (%) 20.3 17.5 0.69
Basal serum creatinine (mg/dL): median (IQR) 1.20 (1.00) 1.30 (1.25) 0.16
RIFLE criteria (%)  0.02
Risk 30.4 21.2 
Injury 31.6 18.8 
Failure 38.0 60.0 
Basal serum albumin (g/dL): median (IQR) 2.88 (0.73) 2.19 (0.60) <0.001
Basal hemoglobin (g/dL): median (IQR) 11.36 (1.92) 10.59 (2.23) 0.022
Community-acquired acute renal failure (%) 30.8 45.8 0.15
Liano scoring: median score (IQR) 0.17 (0.21) 0.25 (0.30) 0.03
Karnofsky scoring: median score (IQR) 73.65 (15.27) 63.09 (12.49) <0.001
Hypotension (%) 30.4 42.5 0.139
Oliguria (%) 24.1 43.8 0.012
Jaundice (%) 17.7 31.3 0.065
Coma (%) 7.6 11.3 0.589
Consciousness (%) 81.0 85.0 0.533
Mechanical ventilation (%) 12.7 16.3 0.653
Aminoglycoside use (%) 16.5 22.5 0.42
Radiocontrast procedures (%) 17.7 22.5 0.55
Diabetic (%) 2.5 2.5 1.00
Nephrotoxicity (%) 65.8 58.8 0.41
Causes of acute renal failure  0.46
Pre-renal (%) 78.5 78.2 
Intrinsic renal (%) 15.2 8.8 
Post-renal (%) 2.5 1.2 
Other causes (%) 3.8 8.8 
Treatment of acute renal failure  0.016
Non-dialysis (%) 84.8 66.3 
Intermittent hemodialysis (%) 1.3 11.3 
Continuous replacement therapy (%) 8.9 17.5 
Both (intermittent þ continuous) (%) 5.1 5.0 
Nutrition intake  <0.001
Optimal nutrition (%) 41.2 13.2 
Mild malnutrition (%) 14.7 13.2 
Moderate malnutrition (%) 32.4 22.1 
Severe malnutrition (%) 11.8 51.5 
IQR, interquartile range; MDRD, modification of diet in renal disease. 
*Continuous variables are expressed as median and interquartile range. 
~ p value was tested by Pearson chi square test for categorical variables and Mann-
Whitney U test for continuous variables. 
# Creatinine increase (%) = [(creatinine when nephrologist saw the case e basal 
creatinine)/basal creatinine] * 100. 
Table 3. Hazard ratios (HRs) and 95% confidence intervals of in-hospital mortality for 
different serum C-reactive protein levels and other factors 
 Crude HR      
(95% CI) 
p value Multivariate*   
HR (95% CI) 
p value
C-reactive protein≥8 mg/dL 3.09 (1.78-5.37) <0.001 2.10 (1.17-3.78) 0.013
Liano scoring#   
1 (0.16) 1 (Reference) 1 (Reference)  
2 (0.28) 2.07 (1.01-4.23) 0.040 1.54 (0.73-3.25) 0.260
3 (0.62) 13.78 (7.18-26.45) <0.001 8.23 (4.15-16.33) <0.001
Karnofsky scoring#   
1 (50) 1 (Reference) 1 (Reference)  
2 (60) 0.39 (0.20-0.75) 0.005 0.56 (0.28-1.12) 0.09
3 (90) 0.05 (0.02-0.18) <0.001 0.14 (0.04-0.55) 0.004
Age (for every year older) 1.02 (0.99-1.04) 0.08 1.01 (0.99-1.03) 0.31
Sex (male) 0.97 (0.58-1.61) 0.90 0.92 (0.53-1.61) 0.78
*Adjusted for all the variables included in the table. 
 
#Expressed as tertiles and (median). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Cumulative survival. 
